10-Q: BIOLASE Reports Q2 2024 Results Amidst Financial Challenges and Nasdaq Delisting

BIOLASE's Q2 2024 results reveal a decrease in revenue and a net loss, alongside ongoing concerns about the company's ability to continue as a going concern and its recent delisting from the Nasdaq.

Summary

• BIOLASE reported a net revenue of $11.6 million for the three months ended June 30, 2024, a decrease from $14.3 million in the same period of 2023.
• The company's net loss for the quarter was $2.8 million, compared to a net loss of $4.9 million in the second quarter of 2023.
• For the six months ended June 30, 2024, net revenue was $21.7 million, down from $24.8 million in the first half of 2023, with a net loss of $9.3 million compared to $10.7 million in the prior year.
• The company's working capital deficit was approximately $9.1 million as of June 30, 2024, primarily due to the SWK Loan maturing in May 2025.
• BIOLASE's cash and cash equivalents stood at $5.3 million as of June 30, 2024, a decrease from $6.6 million at the end of 2023.
• The company's financial statements do not include any adjustments that might be necessary if the company is unable to continue as a going concern.
• BIOLASE's common stock was delisted from the Nasdaq on June 20, 2024, and is now trading on the OTCQB market.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with declining revenue, net losses, a working capital deficit, and delisting from Nasdaq. While there are some positive aspects like the recent public offering, the overall sentiment is negative due to the substantial risks and uncertainties surrounding the company's future.

Positives

• The net loss for Q2 2024 was lower than the net loss for Q2 2023.
• The company completed a public offering in February 2024, raising gross proceeds of approximately $7.0 million.
• The company is forecasting revenue for fiscal year 2024 to be above fiscal year 2023.

Negatives

• Net revenue decreased by 19% in Q2 2024 compared to Q2 2023.
• The company's working capital deficit was approximately $9.1 million as of June 30, 2024.
• The company's cash and cash equivalents decreased to $5.3 million as of June 30, 2024.
• BIOLASE's common stock was delisted from the Nasdaq on June 20, 2024.
• The company's gross profit margin decreased to 40% in Q2 2024 from 43% in Q2 2023.

Risks

• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of losses and negative cash flow from operations.
• The company may not be able to raise additional capital on acceptable terms.
• The company's common stock is no longer traded on the Nasdaq, which makes it harder to attract investors and limits the types of financings that can be conducted.
• The company is subject to the penny stock rules of the SEC.
• The company is facing a lawsuit alleging patent infringement.

Future Outlook

The company expects that it will be required to raise capital through either equity or debt offerings and is forecasting revenue for fiscal year 2024 to be above fiscal year 2023.

Management Comments

• Management believes that the presentation of non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results.
• Management uses Adjusted EBITDA in its evaluation of our core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process.

Industry Context

The dental laser market is competitive, with BIOLASE facing challenges from both established players and emerging technologies. The company's focus on education and innovation is aimed at maintaining its position in the market. The delisting from Nasdaq and the need for additional capital highlight the financial pressures faced by smaller companies in the medical device sector.

Comparison to Industry Standards

• BIOLASE's revenue decline of 19% in Q2 2024 is worse than the average performance of some of its competitors in the dental equipment industry, which have shown more stable or positive growth.
• The company's gross profit margin of 40% is lower than the industry average for medical device companies, which typically range from 50% to 70%.
• The company's cash position of $5.3 million is relatively low compared to other companies in the sector, raising concerns about its ability to fund operations and growth initiatives.
• The delisting from Nasdaq is a significant negative event, as it reduces the company's visibility and access to capital markets, unlike its peers that maintain listings on major exchanges.
• The company's reliance on a single supplier for key components is a risk factor that is not uncommon in the industry, but it is a vulnerability that needs to be addressed.

Legal Proceedings

• On January 4, 2023, Plaintiff PIPStek, LLC filed a lawsuit against BIOLASE, Inc. alleging that BIOLASE's Waterlase dental laser product infringes two PIPStek patents, with a third patent subsequently added to the case.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and delisting from Nasdaq.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may experience uncertainty regarding the company's long-term viability and product support.
• Suppliers may face increased credit risk due to the company's financial challenges.
• Creditors face increased risk of non-payment due to the company's financial instability.

Next Steps

• The company plans to continue to file its required periodic reports and other filings with the SEC.
• The company will endeavor to improve its financial condition and ultimately improve its financial results by increasing revenues through expansion of its product offerings, continuing to expand and develop its field sales force and distributor relationships both domestically and internationally, forming strategic arrangements within the dental and medical industries, educating dental and medical patients as to the benefits of our advanced medical technologies, and reducing expenses.

Key Dates

Keywords

BIOLASE, dental lasers, financial results, Nasdaq delisting, going concern, revenue, net loss, working capital, public offering, OTC Markets, SWK Loan, preferred stock, warrants